In other disease settings, VEGF-C and VEGF-D are being explored in approaches to drive therapeutic angiogenesis and/or lymphangiogenesis for cardiovascular medicine and lymphedema (9, 20, 21). This evidence concerns the gene VEGFD and lymphedema.